CARM1 and plasma cell myeloma: Studies have reported that the use of selective inhibitors of CARM1 inhibits the proliferation of multiple myeloma cell lines and that affected cells are blocked in the G1 phase [16], which is consistent with our findings using shRNA to knock down CARM1 expression in MM cells.